— Know what they know.
Not Investment Advice
Also trades as: 0J2O.L (LSE) · $vol 0M

HALO Short Interest

Halozyme Therapeutics, Inc.
1W: +3.3% 1M: +13.8% 3M: +54.3% YTD: +82.8% 1Y: +94.3% 3Y: +265.5% 5Y: +231.5%
$128.50
+0.49 (+0.38%)
 
Weekly Expected Move ±4.8%
$114 $120 $126 $132 $138
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Buy · Power 74 · $14.6B mcap · 112M float · 1.95% daily turnover · Short 60% of daily vol
Credit Risk of going bust: lower than 70% of companies Debt: 12.8% of company value Bonds: $229.7M held by 80 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.58B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Short Volume Summary

2026-10-26
57.4%
Short Ratio
of total volume
60.7%
20-Day Avg
56.1%
50-Day Avg
▼ Falling
5-Day Trend
0.3M
Short Volume
0.5M
Total Volume

Daily Short Volume Ratio

Short Volume vs Total Volume

Exchange Breakdown

2026-10-26
ExchangeShort VolumeTotal VolumeShort %
NASDAQ 278,377 484,778 57.4%
NYSE 20,403 34,847 58.5%
BATS 912 2,307 39.5%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms